The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
https://pharmaphorum.com/news/deepmatter-will-help-astrazeneca-digitise-discovery-chemistry/
Very interesting article: https://www.proactiveinvestors.co.uk/companies/news/918334/astrazeneca-plc-may-be-the-uk-s-largest-company-but-it-and-other-pharma-giants-rely-in-small-cap-biotech-for-new-medicines-according-arix-pair-918334.html
Yes buy. NT now lol
looks like a buy. price lowered to fill that order.
1.25 million trade gone through. Is that a Buy?
Big seller in background, once cleared will go up
It will go up soon. Could re rate over a few days
why is the price not rising? There must be about 5 times more buys than sells.
Astra Zeneca could just take these out . Gotta be in it to win it
Parpaing - your arrogance is breath taking - I think I’ll trust the experts on this one and the huge drug company who’ve just decided to collaborate *rolls eyes*
imho DYOR
where do you see theSP here with Astra Zeneca onboard
Drug trials for human use take between 5 to 15 years before they are approved. Using an app and software won't alter this.
Only 20 percent free float. Will move quickly on volume
Michael Kossenjans, Associate Director, Discovery Sciences, R&D, AstraZeneca, said:
"Our goal is to transform drug design using innovative digital technologies in combination with automation and AI. To get potential new medicines to patients faster, we need to reduce the cycle time for lead identification and optimisation and look forward to working with DeepMatter to assess the potential of DigitalGlassware™ to help with this."
Looks likes it's across while product range . Astra Zeneca with billions in sales . This could be significant. Buy
Should do. Bought with my profits on i3e.
I told u guys. Well do good today. 4m cash and first revenue, plus this RNS got to move to over 5p+
150k buy gone through.
4m cash as of date, first revenue few months ago , and coll with astra , super
Astra who?